News | Contrast Media | November 30, 2018

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking

NINJA system uses dashboards to display patient data related to exposure criteria in real time

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati Children’s research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for acute kidney injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Stuart L. Goldstein, M.D., FAAP, FNKF, director of the Center for Acute Care Nephrology and primary researcher on NINJA.  “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates the time-consuming manual screening process of evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye and recent renal testing. For medications, manual screening is limited to the last 24 hours; the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

For more information: www.vigilanzcorp.com

Related AKI Content

Understanding Contrast-Induced Nephropathy

VIDEO: How to Avoid Acute Kidney Injury in the Cath Lab

 

Related Content

News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
News | Cath Lab

November 10, 2021 — Shockwave Medical a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...

Home November 10, 2021
Home
News | Cath Lab

November 10, 2021 — Philips Healthcare announced North American availability of new innovations in its portfolio of ...

Home November 10, 2021
Home
Subscribe Now